MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death

Molecular and Cellular Biochemistry

Volumn 382, Issue 1-2, 2013, Pages 217-224

  Jiao, Peng ^a   Zhou, Yun Sheng ^b   Yang, Juan Xia ^c   Zhao, Ya Li ^a   Liu, Qiang Qiang ^a   Yuan, Chuang ^a   Wang, Feng Ze ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b Central Hospital of Taian   (China)

^c Shandong Provincial Key Laboratory of Fruit Tree Biotechnology Breeding   (China)

Author keywords

Cell apoptosis; HepG2 cell; MK 2206; PI3K AKT; TRAIL

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CASPASE 3; CASPASE 7; CASPASE 9; CYCLIN B1; CYCLIN D1; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROPIDIUM IODIDE; PROTEIN P21; PROTEIN P27; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN HEPG2; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INDUCTION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASES; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HEP G2 CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84884611933     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1737-0     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
2. Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19(8):1893-1907. doi: 10.1158/1055-9965
3. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365(12):1118-1127. doi: 10.1056/NEJMra1001683
4. Carbajo-Pescador S, Steinmetz C, Kashyap A, Lorenz S, Mauriz JL, Heise M, Galle PR, González-Gallego J, Strand S (2013) Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells. Br J Cancer 108(2):442-449. doi: 10.1038/bjc.2012.563
5. Altomare DA, Khaled AR (2012) Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem 19(22):3748-3762. doi: CMC-EPUB-20120607-24
6. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96(6):857-868. doi: S0092-8674(00)80595-4
7. Choudhury GG, Mahimainathan L, Das F, Venkatesan B, Ghosh-Choudhury N (2006) c-Src couples PI3 kinase/Akt and MAPK signaling to PDGF-induced DNA synthesis in mesangial cells. Cell Signal 18(11):1854-1864. doi: 10.1016/j.cellsig.2006.02.003
8. Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W, Yuan Z, Wang LH, Cheng JQ (2008) Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr Cancer Drug Targets 8(1):2-6
9. Osaki M, Oshimura M, Ito H (2004) PI3 K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9(6):667-676. doi: 10.1023/B:APPT. 0000045801.15585.dd
10. Lindsley CW (2010) The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 10(4):458-477
11. Cheng Y, Ren X, Zhang Y, Patel R, Sharma A, Wu H, Robertson GP, Yan L, Rubin E, Yang JM (2011) eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res Cancer Res 71(7):2654-2663. doi: 10.1158/0008-5472.CAN-10-2889
12. Jin R, Nakada M, Teng L, Furuta T, Sabit H, Hayashi Y, Demuth T, Hirao A, Sato H, Zhao G, Hamada JI (2013) Combination therapy using notch and akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells. Neurosci Lett 534:316-321. doi: 10.1016/j.neulet.2012.12.008
13. Lan Y, Liu X, Zhang R, Wang K, Wang Y (2013) Hua ZC (2013) Lithium enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. Biometals. doi: 10.1007/s10534-012-9607-x
14. Carlisi D, D'Anneo A, Angileri L, Lauricella M, Emanuele S, Santulli A, Vento R, Tesoriere G (2011) Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol 226(6):1632-1641. doi: 10.1002/jcp.22494
15. Charette N, De Saeger C, Horsmans Y, Leclercq I, Stärkel P (2013) Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms. Cell Death Dis 4:e471. doi: 10.1038/cddis.2012.200
16. Woo JS, Kim SM, Jeong CH, Ryu CH, Jeun SS (2013) Lipoxygenase inhibitor MK886 potentiates TRAIL-induced apoptosis through CHOP- and p38 MAPK-mediated up-regulation of death receptor 5 in malignant glioma. Biochem Biophys Res Commun 431(2):354-359. doi: 10.1016/j.bbrc.2012.11.134
17. Wang S (2008) The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27(48):6207-6215. doi: 10.1038/onc.2008.298
18. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6(3):184-192. doi: 10.1038/nrc1819
19. Jung KH, Zheng HM, Jeong Y, Choi MJ, Lee H, Hong SW, Lee HS, Son MK, Lee S, Hong S, Hong SS (2013) Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor. Cancer Lett 328(1):176-187. doi: 10.1016/j.canlet.2012.08.005
20. Somnay Y, Simon K, Harrison AD, Kunnimalaiyaan S, Chen H, Kunnimalaiyaan M (2013) Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro. Anticancer Drugs 24(1):66-72. doi: 10.1097/CAD.0b013e3283584f75
21. Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M (2011) The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab 96(4):E577-E585. doi: 10.1210/jc.2010-2644
22. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F (2012) Biomarkers of response to akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 18(20):5816-5828. doi: 10.1158/1078-0432.CCR-12-1141
23. Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, Hines J, Chen X (2012) A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 11(8):1672-1682. doi: 10.1158/1535-7163.MCT-12-0131
24. Widmann C, Gibson S, Johnson GL (1998) Caspase-dependent cleavage of signaling proteins during apoptosis. A turn-off mechanism for anti-apoptotic signals. J Biol Chem 273(12):7141-7147
25. Chun J, Joo EJ, Kang M, Kim YS (2013) Platycodin D induces anoikis and caspase-mediated apoptosis via p38 MAPK in AGS human gastric cancer cells. Cell Biochem 114(2):456-470. doi: 10.1002/jcb.24386
26. Siegelin MD (2012) Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis. Expert Opin Ther Targets 16(8):801-817. doi: 10.1517/14728222.2012.703655
27. Hellwig CT, Rehm M (2012) TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 11(1):3-13. doi: 10.1158/1535-7163.MCT-11-0434
28. Maksimovic-Ivanic D, Stosic-Grujicic S, Nicoletti F, Mijatovic S (2012) Resistance to TRAIL and how to surmount it. Immunol Res 52(1-2):157-168. doi: 10.1007/s12026-012-8284-8
29. Abou El Naga RN, Azab SS, El-Demerdash E, Shaarawy S, El-Merzabani M, Ammar el-SM (2013) Sensitization of TRAIL-induced apoptosis in human hepatocellular carcinoma HepG2 cells by phytochemicals. Life Sci 92(10):555-561. doi: 10.1016/j.lfs.2013.01.017
30. Wang G, Wang X, Yu H, Wei S, Williams N, Holmes DL, Halfmann R, Naidoo J, Wang L, Li L, Chen S, Harran P, Lei X, Wang X (2013) Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol 9(2):84-89. doi: 10.1038/nchembio.1153
31. Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM (2008) Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 68(22):9394-9403. doi: 10.1158/0008-5472.CAN-08-2815